Literature DB >> 33129844

PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.

Woosook Kim1, Timothy H Chu1, Henrik Nienhüser1, Zhengyu Jiang1, Armando Del Portillo2, Helen E Remotti2, Ruth A White1, Yoku Hayakawa3, Hiroyuki Tomita4, James G Fox5, Charles G Drake6, Timothy C Wang7.   

Abstract

BACKGROUND & AIMS: Immune checkpoint inhibitors have limited efficacy in many tumors. We investigated mechanisms of tumor resistance to inhibitors of programmed cell death-1 (PDCD1, also called PD-1) in mice with gastric cancer, and the role of its ligand, PD-L1.
METHODS: Gastrin-deficient mice were given N-methyl-N-nitrosourea (MNU) in drinking water along with Helicobacter felis to induce gastric tumor formation; we also performed studies with H/K-ATPase-hIL1B mice, which develop spontaneous gastric tumors at the antral-corpus junction and have parietal cells that constitutively secrete interleukin 1B. Mice were given injections of an antibody against PD-1 or an isotype control before tumors developed, or anti-PD-1 and 5-fluorouracil and oxaliplatin, or an antibody against lymphocyte antigen 6 complex locus G (also called Gr-1), which depletes myeloid-derived suppressor cells [MDSCs]), after tumors developed. We generated knock-in mice that express PD-L1 specifically in the gastric epithelium or myeloid lineage.
RESULTS: When given to gastrin-deficient mice before tumors grew, anti-PD-1 significantly reduced tumor size and increased tumor infiltration by T cells. However, anti-PD-1 alone did not have significant effects on established tumors in these mice. Neither early nor late anti-PD-1 administration reduced tumor growth in the presence of MDSCs in H/K-ATPase-hIL-1β mice. The combination of 5-fluorouracil and oxaliplatin reduced MDSCs, increased numbers of intra-tumor CD8+ T cells, and increased the response of tumors to anti-PD-1; however, this resulted in increased tumor expression of PD-L1. Expression of PD-L1 by tumor or immune cells increased gastric tumorigenesis in mice given MNU. Mice with gastric epithelial cells that expressed PD-L1 did not develop spontaneous tumors, but they developed more and larger tumors after administration of MNU and H felis, with accumulation of MDSCs.
CONCLUSIONS: In mouse models of gastric cancer, 5-fluorouracil and oxaliplatin reduce numbers of MDSCs to increase the effects of anti-PD-1, which promotes tumor infiltration by CD8+ T cells. However, these chemotherapeutic agents also induce expression of PD-L1 by tumor cells. Expression of PD-L1 by gastric epithelial cells increases tumorigenesis in response to MNU and H felis, and accumulation of MDSCs, which promote tumor progression. The timing and site of PD-L1 expression is therefore important in gastric tumorigenesis and should be considered in design of therapeutic regimens.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunosuppression; Mouse Model; Resistance; Stomach Cancer

Mesh:

Substances:

Year:  2020        PMID: 33129844      PMCID: PMC7878361          DOI: 10.1053/j.gastro.2020.10.036

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  46 in total

1.  Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing.

Authors:  Hiroyuki Tomita; Shigeo Takaishi; Trevelyan R Menheniott; Xiangdong Yang; Wataru Shibata; Guangchun Jin; Kelly S Betz; Kazuyuki Kawakami; Toshinari Minamoto; Catherine Tomasetto; Marie-Christine Rio; Nataporn Lerkowit; Andrea Varro; Andrew S Giraud; Timothy C Wang
Journal:  Gastroenterology       Date:  2010-11-25       Impact factor: 22.682

2.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.

Authors:  Jing Li; Lujun Chen; Yuqi Xiong; Xiao Zheng; Quanqin Xie; Qi Zhou; Liangrong Shi; Changping Wu; Jingting Jiang; Haitao Wang
Journal:  Cell Physiol Biochem       Date:  2017-02-20

4.  CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer.

Authors:  Dingzhi Wang; Haiyan Sun; Jie Wei; Bo Cen; Raymond N DuBois
Journal:  Cancer Res       Date:  2017-04-28       Impact factor: 12.701

5.  Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

Authors:  Salah-Eddin Al-Batran; Joerg Thomas Hartmann; Stephan Probst; Harald Schmalenberg; Stephan Hollerbach; Ralf Hofheinz; Volker Rethwisch; Gernot Seipelt; Nils Homann; Gerhard Wilhelm; Gunter Schuch; Jan Stoehlmacher; Hans Günter Derigs; Susanna Hegewisch-Becker; Johannes Grossmann; Claudia Pauligk; Akin Atmaca; Carsten Bokemeyer; Alexander Knuth; Elke Jäger
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

6.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Authors:  Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

7.  Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice.

Authors:  Shuiping Tu; Govind Bhagat; Guanglin Cui; Shigeo Takaishi; Evelyn A Kurt-Jones; Barry Rickman; Kelly S Betz; Melitta Penz-Oesterreicher; Olle Bjorkdahl; James G Fox; Timothy C Wang
Journal:  Cancer Cell       Date:  2008-11-04       Impact factor: 31.743

8.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

Review 9.  Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity.

Authors:  Louise A Elliott; Glen A Doherty; Kieran Sheahan; Elizabeth J Ryan
Journal:  Front Immunol       Date:  2017-02-06       Impact factor: 7.561

Review 10.  PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.

Authors:  Yilun Wu; Weiyu Chen; Zhi Ping Xu; Wenyi Gu
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

View more
  21 in total

Review 1.  Signaling pathways and therapeutic interventions in gastric cancer.

Authors:  Zi-Ning Lei; Qiu-Xu Teng; Qin Tian; Wei Chen; Yuhao Xie; Kaiming Wu; Qianlin Zeng; Leli Zeng; Yihang Pan; Zhe-Sheng Chen; Yulong He
Journal:  Signal Transduct Target Ther       Date:  2022-10-08

2.  An immunosuppressive scoring system to predict recurrence and assist in decision regarding postoperative adjuvant treatment in gastric cancer.

Authors:  Jiabin Wang; Qingzhu Qiu; Ningzi Lian; Huagen Wang; Qiaoling Zheng; Yinghong Yang; Yubin Ma; Yajun Zhao; Ping Li; Jianxian Lin; Jun Lu; Qiyue Chen; Longlong Cao; Mi Lin; Changming Huang; Jianwei Xie
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

Review 3.  Immunogenetics of gastrointestinal cancers: A systematic review and retrospective survey of inborn errors of immunity in humans.

Authors:  Beishi Zheng; Michael G Artin; Howard Chung; Bing Chen; Siming Sun; Benjamin L May; Chin Hur; Peter H R Green; Timothy C Wang; Jiheum Park; Xiao-Fei Kong
Journal:  J Gastroenterol Hepatol       Date:  2022-04-13       Impact factor: 4.369

4.  Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.

Authors:  Long Qin; Long Wang; Junchang Zhang; Huinian Zhou; Zhiliang Yang; Yan Wang; Weiwen Cai; Fei Wen; Xiangyan Jiang; Tiansheng Zhang; Huili Ye; Bo Long; Junjie Qin; Wengui Shi; Xiaoying Guan; Zeyuan Yu; Jing Yang; Qi Wang; Zuoyi Jiao
Journal:  Sci Adv       Date:  2022-05-25       Impact factor: 14.957

Review 5.  Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.

Authors:  Yan Tie; Fan Tang; Yu-Quan Wei; Xia-Wei Wei
Journal:  J Hematol Oncol       Date:  2022-05-18       Impact factor: 23.168

Review 6.  The role of myeloid-derived suppressor cells in gastrointestinal cancer.

Authors:  Cheng Cui; Penglin Lan; Li Fu
Journal:  Cancer Commun (Lond)       Date:  2021-03-27

7.  Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.

Authors:  Leonie K de Klerk; Anuj K Patel; Peter C Enzinger; Adam J Bass; Sarah Derks; Eirini Pectasides; Jeremy Augustin; Mohamed Uduman; Nihal Raman; Fahire G Akarca; Nadine J McCleary; James M Cleary; Douglas A Rubinson; Jeffrey W Clark; Bridget Fitzpatrick; Lauren K Brais; Megan E Cavanaugh; Amanda J Rode; Melissa G Jean; Patrick H Lizotte; Matthew J Nazzaro; Mariano Severgnini; Hui Zheng; Charles S Fuchs
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

Review 8.  Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies.

Authors:  Kevin Park; Mysore S Veena; Daniel Sanghoon Shin
Journal:  Front Cell Dev Biol       Date:  2022-03-08

9.  circ-0007707/miR-429/PDGFD Pathway Regulates the Progression of Gastric Cancer by Modulating the Immune-Gene Signature.

Authors:  Yang Yang; Weibiao Kang; Yu Yuan; Chen Duan; Wei Chen; Changjun Yu
Journal:  J Oncol       Date:  2022-04-25       Impact factor: 4.501

Review 10.  Aberrant lipid metabolism reprogramming and immune microenvironment for gastric cancer: a literature review.

Authors:  Meng-Ying Cui; Xing Yi; Dan-Xia Zhu; Jun Wu
Journal:  Transl Cancer Res       Date:  2021-08       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.